[Skip to Navigation]
Comment & Response
August 2018

Questioning the Associations of ω-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks—Reply

Author Affiliations
  • 1Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England
JAMA Cardiol. 2018;3(8):781-782. doi:10.1001/jamacardio.2018.1312

In Reply The recent Omega-3 Treatment Trialists’ Collaboration report1 provided an updated summary of the results of 10 large randomized trials and involved almost 78 000 people treated with ω-3 fatty acid supplements for a mean of 5 years for the prevention of cardiovascular disease. The results demonstrated no significant associations of ω-3 fatty acid treatment with coronary heart disease (CHD) death (rate ratio [RR], 0.93; 99% CI, 0.83-1.03; P = .053), nonfatal myocardial infarction (RR, 0.97; 99% CI, 0.87-1.08; P = .43), or any CHD events (RR, 0.96; 95% CI, 0.90-1.01; P = .12). In contrast with previous meta-analyses,2,3 this meta-analysis was conducted by the lead investigators of the individual trials and included analyses that distinguished the effects of ω-3 fatty acids on subtypes of CHD and the effects of ω-3 fatty acids on major vascular events in population subgroups (by age, sex, prior vascular disease, diabetes, or lipid levels).